Sun Pharma, Ranbaxy rise after regulatory nods for merger deal

Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories today settled in the positive territory after regulatory nods paved the way for completion of their USD 4-billion merger.
Reacting to these developments, shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories today surged as much as 2.51 per cent and 2.83 per cent respectively to touch an intra-day high of Rs 1049 and Rs 827.40.
At the end of today's trade, Sun Pharmaceutical Industries ended at Rs 1,039.85, up 1.55 per cent and Ranbaxy Laboratories closed at Rs 819.55 apiece, up 1.86 per cent.
Sun Pharmaceutical Industries is slated to make an important announcement on Wednesday.

The Dilip Shanghvi-led firm today said it has received RBI nod for transfer of overseas investments of Ranbaxy to it and issue its shares to the non-resident shareholders of the latter as part of their USD 4-billion merger deal.
The central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, the filing added.
The two firms have also received nod from the Competition Commission for sale of seven brands to Emcure Pharma to comply with the fair trade watchdog's conditional nod for their merger.
In an order issued yesterday, CCI approved the deal with Emcure, which would purchase the 'divestment products' that were ordered to be sold in an earlier direction issued in December last by the Competition Commission of India (CCI).